Candid Therapeutics: Under Agreement, Epimab Entitled to Obtain Upfront Payment, and Development & Sales Milestones Totaling Over $1 Bln
Candid Therapeutics:根据协议,Epimab 有权获得预付款,以及总计超过 10 亿美元的发展和销售里程碑
Candid Therapeutics: Under Agreement, Epimab Entitled to Obtain Upfront Payment, and Development & Sales Milestones Totaling Over $1 Bln
Candid Therapeutics:根据协议,Epimab 有权获得预付款,以及总计超过 10 亿美元的发展和销售里程碑
使用浏览器的分享功能,分享给你的好友吧